Clinical trial NCT00938678: Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers
Official title: A Phase I, Randomized, Single Dose, Crossover Study Evaluating the Pharmacokinetics and Pharmacodynamics of Pegfilgrastim Hospira Compared to Neulasta (Amgen) Following Subcutaneous Administration to Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy volunteers
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2009-07-14
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study compared the pharmacokinetics, pharmacodynamics and the safety of Pegfilgrastim Hospira and Neulasta® following a single dose of 6 mg of each product administered subcutaneously in Treatment Periods 1 and 2, respectively, in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male or female subjects, 18-55 years inclusive.
* Written informed consent given
* Willing and able to comply with the requirements of the protocol and be available for the planned duration of the study.
* Body Mass Index (BMI) between 19 and 30 kg/m2 inclusive and weight not \<50 kg or \>100 kg.
* Female subjects who are using an effective method of contraception, or are surgically sterile.
* Non-smokers or ex-smokers who have not smoked within the previous 12 months.

Exclusion Criteria:

* Hypersensitivity to the Investigational medicinal product (IMP) or its constituents and/or hypersensitivity to E. Coli derived proteins, and/or previous exposure to the IMP.
* History or presence of any clinically significant findings that, in the opinion of the Investigator, would preclude inclusion in the study.
* History or presence of any clinically significant gastrointestinal pathology or symptoms, liver or kidney disease, or any other condition that might interfere with the absorption, distribution, metabolism or excretion of the drug.
* Any clinically significant laboratory findings, including any ANC, platelet or haemoglobin result outside the reference range of the local laboratory.
* Abnormal vital signs or abnormal 12-lead electrocardiogram (ECG) results, as judged by the Investigator to be clinically significant.
* Females, pregnant or lactating, or planning to become pregnant during the time the subject is on study.
* Subjects with a history of pulmonary infiltrate or pneumonia in the previous 6 months from the date of the screening visit.
* Hereditary fructose intolerance.
* Participation in any other clinical trial using a investigational product or device, within the previous 12 weeks from the date of the screening visit.
* Positive result for human immunodeficiency virus (HIV) and/or hepatitis B and C tests.
* Evidence of, or treatment for, drug or alcohol abuse within one year from date of screening visit.
* Blood donation \>=500 mL in the previous 12 weeks from the date of the screening visit.
* Use of any prescription medication (excluding hormonal contraceptives) within 14 days prior to date of the screening visit.
* Receipt of over-the-counter medicines which have not yet cleared from the body (five half-lives must have passed for the medicine to be considered to have cleared from the body). Vitamins, minerals and nutritional supplements may be taken at the discretion of the Investigator.

Primary outcomes:
measure: Area under the curve from time 0 extrapolated to infinity (AUC0-∞) for serum Pegfilgrastim (PEG-GCSF)
timeFrame: Treatment Periods 1 and 2: Pre-dose (-15 min) and post-dose 1, 2, 4, 6, 8, 10, 16, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2 hours or early discontinuation.
measure: Area under the curve from time 0 to the last time point (AUC0-t) for serum Pegfilgrastim (PEG-GCSF)
timeFrame: Treatment Periods 1 and 2: Pre-dose (-15 min) and post-dose 1, 2, 4, 6, 8, 10, 16, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2 hours or early discontinuation.
measure: Pharmacodynamics: Maximum change from baseline in absolute neutrophil count (ANC); ANC_Cmax
timeFrame: Screening, Day -1, Treatment Periods 1 & 2: Pre-dose (-60 min, -30 min, 0 min), Post dose (12 hr, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2)
Secondary outcomes:
measure: Maximum concentration (Cmax) for serum Pegfilgrastim (PEG-GCSF)
timeFrame: Treatment Periods 1 and 2: Pre-dose (-15 min) and post-dose 1, 2, 4, 6, 8, 10, 16, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2 hours or early discontinuation.
measure: Time to maximum concentration (Tmax) for serum Pegfilgrastim (PEG-GCSF)
timeFrame: Treatment Periods 1 and 2: Pre-dose (-15 min) and post-dose 1, 2, 4, 6, 8, 10, 16, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2 hours or early discontinuation.
measure: Terminal elimination rate constant (λz) for serum Pegfilgrastim (PEG-GCSF)
timeFrame: Treatment Periods 1 and 2: Pre-dose (-15 min) and post-dose 1, 2, 4, 6, 8, 10, 16, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2 hours or early discontinuation.
measure: Half-life (T½) for serum Pegfilgrastim (PEG-GCSF)
timeFrame: Treatment Periods 1 and 2: Pre-dose (-15 min) and post-dose 1, 2, 4, 6, 8, 10, 16, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2 hours or early discontinuation.
measure: Area under the curve above baseline of ANC [ANC_AUC(0-tlast)]
timeFrame: Screening, Day -1, Treatment Periods 1 & 2: Pre-dose (-60 min, -30 min, 0 min), Post dose (12 hr, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2)
measure: Time of maximum change from baseline for ANC in days (ANC_Tmax)
timeFrame: Screening, Day -1, Treatment Periods 1 & 2: Pre-dose (-60 min, -30 min, 0 min), Post dose (12 hr, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2, 264±2, 288±2)
measure: Maximum change from baseline in CD34+ count (CD34+_Cmax)
timeFrame: Day -1, Treatment Periods 1 & 2: Post dose (12 hr, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2)
measure: Time of maximum change from baseline for CD34+ count in days (CD34+_Tmax)
timeFrame: Day -1, Treatment Periods 1 & 2: Post dose (12 hr, 24±2, 48±2, 72±2, 96±2, 120±2, 144±2, 168±2, 192±2, 216±2, 240±2)
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: Quotient Clinical Ltd
Study officials:
References: